In a randomized controlled trial including 51 patients with AD, 8 weekly intramuscular injections of autologous total IgG (50 mg) for 7 weeks resulted in significant clinical improvements and increased serum levels of IL-10 and interferon (IFN)-γ at week 16 (66). The gene discussed is IL10; the disease is Alzheimer disease.